The FY19 Defense Appropriation provides $15 million (M) to the Department of Defense Combat Readiness – Medical Research Program (CRRP) to support military-relevant advanced technology and therapeutic research related to forward-deployable solutions that can promptly address life-threatening injuries, medical threats, and treatments for Service members in current and future battlefield settings. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Broad Agency Announcement/Funding Opportunity is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).
The Congressional language for the CRRP encompasses research that would enable the Warfighter to better respond to serious injury, as well as solutions to mitigate the long-term effects of battlefield trauma. The CRRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications. FY19 CRRP Broad Agency Announcement and General Submission Instructions for the following award mechanism are anticipated to be posted on the Grants.gov website in August 2019. Pre-application and application deadlines will be available when the Broad Agency Announcement is released. This pre-announcement should not be construed as an obligation by the Government.
FY19 CRRP will solicit research applications addressing at least one of the Focus Areas described below. The Focus Areas broadly describe current needs to ensure readiness for delivering front-line care in combat situations, and for delivering medical damage control capability, assets, and life-saving interventions to address the emerging needs of the Warfighter and Service medics during prolonged and en route care in austere and combat environments, including the acute and early management of combat-related trauma at the point of injury.
Applications submitted to the FY19 CRRP must address at least one of the following four Focus Areas:
- Scalable solutions for wound care that can address prevention of bleeding, infection, and acute pain; delivery of therapeutics (including non-opioid solutions for pain); and promotion of healing
- Decision-support solutions, such as algorithms, artificial intelligence, deep learning, and/or telemedicine, for triage and management of severely injured Warfighters, to include management and monitoring of:
o Hemorrhage and resuscitation (i.e., airway management, control of bleeding, sedation, etc.)
o Acute pain
o Multi-casualty events when delayed evacuation exceeds available capability and/or capacity, in order to extend provider capabilities
- Solutions that address hemorrhage control, including:
o Non-compressible torso hemorrhage
o Alternatives to optimize logistics and administration of blood products to the Warfighter
- Wearable sensors with broader multiple capabilities to identify and monitor medical management of injuries, to include:
o Environmental exposures
o Onset of infection, including sepsis
o Physiological status (heart rate, blood pressure, respiration), stress monitoring tools
o Neurological injury
o Point-of-care imaging
Additional concurrent research approaches that address mitigation of long-term physical and psychological complications that occur from poor management of trauma pain and trauma care, as well as treatments for sepsis and new therapies for multidrug-resistant pathogens, including applications to sepsis, wound care, and injuries incurred outside the battlefield are encouraged, but not required.
https://cdmrp.army.mil/pubs/press/2019/19crrppreann
Rapid Development and Translational Research Award
- Extramural applicants only
- Independent investigators at all academic levels (or equivalent)
- Preproposal in the form of a Letter of Intent is required.
- Supports research that will accelerate the movement of promising ideas into clinical applications, including healthcare products, technologies, and/or practice guidelines.
- Preclinical research, including animal studies, that is already supported by substantial preliminary or published data and strongly validates clinical translation is appropriate.
- Research involving human subjects and human anatomical substances is permitted; however, clinical trials are not allowed.
- Maximum funding of $1,500,000 for direct costs (plus indirect costs)
- Maximum period of performance is 2 years
A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.orgprior to the pre-application deadline. All applications must conform to the final Broad Agency Announcement and General Submission Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.
Submission deadlines are not available until the Broad Agency Announcement is released. For email notification when Broad Agency Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the CRRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).
Point of Contact:
CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil
